Publications by authors named "W F Schramm"
The treatment landscape for haemophilia continues to rapidly develop, and expectations for future treatment success are high. There is limited information on the challenges to accessing new and innovative therapies. The aim of this study was to explore challenges with accessing haemophilia treatment from the perspective of healthcare professionals (HCPs).
View Article and Find Full Text PDFConvalescent plasma was proposed for passive immunization against COVID-19; but so far there are conflicting results and still open questions. However, besides antibodies, other plasma proteins may be good candidates for further research and application. Thromboinflammation frequently complicates severe COVID-19, and classical anticoagulants like heparins seem to have limited effect.
View Article and Find Full Text PDFIntroduction: Prethrombin-1 is a Gla-domain lacking enzymatically inactive split product that results from the cleavage of fragment 1 from prothrombin by thrombin in a feedback reaction.
Methods: A prethrombin-1 preparation derived from human plasma was tested for its hemostatic and thrombogenic properties. Animal models of nail clipping (for rabbits) and tail clipping (for mice) were developed to measure blood loss in FVIII-inhibitor or rivaroxaban anticoagulated rabbits and mice, respectively.
Article Synopsis
- Cathepsin B (CtsB) is a protease linked to various health conditions and its absence in mice was examined to understand diabetic kidney disease induced by streptozotocin (STZ).
- Analysis of urinary extracellular vesicles (uEVs) revealed specific bioactive lipids associated with oxidative stress and renal cell death in CtsB knockout mice treated with STZ.
- Findings indicate that STZ treatment activates antioxidant responses in the kidneys but primarily leads to apoptosis (programmed cell death) rather than ferroptosis, highlighting key mechanisms in diabetic kidney disease development.
Background: Next-generation sequencing liquid biopsy (NGS-LB) for colorectal cancer (CRC) detection and surveillance remains an expensive technology as economies of scale have not yet been realized. Nevertheless, the cost of sequencing has decreased while sensitivity has increased, raising the question of whether cost-effectiveness (CE) has already been achieved from the perspective of European healthcare systems.
Objectives: This health economic (HE) modeling study explores the CE of NGS-LB for CRC based on direct treatment costs compared to standard care without liquid biopsy in Spain, France, and Germany.